FIG. 2.

JNKAS treatment effectively inhibits JNK expression in MCF-7 and RKO cells regardless of p53 status. (A) Total RNA was extracted from cells 24 h following treatment with 0.3 μM JNK1AS, JNK2AS, or control oligonucleotides (JNKScr). RNA samples were analyzed by Northern analysis using cDNA probes specific for JNK1 and JNK2 mRNAs. (B) Whole-cell lysates were examined by Western analysis for JNK expression 24 h following treatment with JNKAS oligonucleotides. (C) Total Jun kinase activity was determined 30 min following exposure to UVC (40 J/m²) by an in vitro kinase assay using GST-cJun(1-222) as a substrate. At 24 h prior to UVC treatment, cells were transfected with combinations of JNK1AS plus JNK2AS (0.15 μM each) or JNK1Scr plus JNK2Scr (0.15 μM each) (labeled JNKAS and JNKScr, respectively).